For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Date: October 26- 27, 2021
MetroFlow is a resource for people in the New York metropolitan area involved in the field of analytical cytology; and mostly for those utilizing Flow Cytometry technology. Their annual meeting, MetroFlow 2021 will span two half days in October 2021. This event will include scientific talks, vendor presentations, and round table discussions around data analysis, full spectrum and conventional flow, future of cell sorting, and cytometry reagents.
Abcam’s expertise supports the creation of high-quality products that meet our global customers’ complex research requirements, including high-throughput immunoassays and custom antibody services. Our world-leading immunoassays and antibodies are essential across multiple applications within drug discovery, diagnostics, and basic research. We partner with our customers, listening closely to their needs, to produce unique, tailor-made solutions.
Abcam's Participation at MetroFlow 2021
Vendor Presentation: FirePlex- a Versatile Multiplexed Assay Technology Platform
Presenters: Glen Marsz, Strategic Account Manager, Abcam & Ozge Getkin, Field Application Specialist, Abcam
Date/ Time: Tuesday, October 26th | 11:35 AM- 11:50 AM
Multiplexed assay technologies facilitate biomedical research and expedite discovery, as they allow harvesting more information from each experiment. By their virtue, these technologies accelerate data driven decision making and enhance the rate of incidental observations. Moreover, researchers are increasingly interested in molecular signatures and systems-level view because of the broad acceptance that measuring a single molecule cannot adequately capture the complexity of a biological process or define a disease state. Novel technological advances have made remarkable contributions to moving science forward at an unprecedented pace but have also led to a rise in the financial cost of leveraging the scientific process. To counteract this, laboratories both in academia and in industry are continuously seeking for ways to maximize resources and extract more value from existing assets. To help address these challenges, Abcam has developed FirePlex - a particle-based multiplexed assay technology platform. FirePlex enables advanced multiplexing while utilizing ubiquitously found benchtop flow cytometers. The capabilities afforded by FirePlex also include absolute quantification of target analytes directly from crude biofluids. Furthermore, the FirePlex assay platform was developed to measure either proteins or miRNAs, thus expanding the explored biological space. These features make the FirePlex assay technology of a broad utility in various research settings from basic research through drug-discovery and translational research. Technology principles, assay workflow and real-world examples will be presented.
Have questions about Abcam's participation at MetroFlow 2021 or interesting in meeting with our presenters 1:1? Contact email@example.com